Ascend Laboratories LLC. is voluntarily recalling Dabigatran Etcxilate Capsules due to the presence of a NDSRI, N-nitroso-dabigatran, above the established Acceptable Daily Intake (ADI) level
|
|
2
|
98
|
March 27, 2023
|
Unofficial/official surrogates for read-across
|
|
5
|
289
|
March 27, 2023
|
NDSRIs standards (for confirmatory testing or ames/other tests)
|
|
7
|
317
|
March 24, 2023
|
Drawing a line: Where might the cohort of concern end?
|
|
1
|
270
|
March 21, 2023
|
Formation of Dialkyl-N-nitrosamines in Aqueous Solution: An Experimental Validation of a Conservative Predictive Model and a Comparison of the Rates of Dialkyl and Trialkylamine Nitrosation
|
|
6
|
285
|
February 25, 2023
|
APIC NA Risk Assessment Template
|
|
3
|
137
|
December 19, 2022
|
Pfizer Japan to Curb Shipments and Recall Amoxapine over Carcinogen Risks
|
|
3
|
164
|
November 10, 2022
|